Floatz logo

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN)

Transitional Cell Carcinoma of Bladder

Altor BioScienceprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Transitional Cell Carcinoma of Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

TCR .ALPHA..BETA. (RECEPTOR), ANTI-(HUMAN P53 (PROTEIN)) (SYNTHETIC HUMAN SINGLE-CHAIN PRECURSOR) FUSION PROTEIN WITH INTERLEUKIN 2 (HUMAN) is also rated in:

obesity disorderDormant
CCC
Indicative ·
53 / 100
View asset →
urethra cancerDormant
CCC
Indicative ·
52 / 100
View asset →
malignant renal pelvis neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →